# JUL 14 2006

Mr. Jian Vaeches   
R & D Department   
Teco Diagnostics   
1268 N. Lakeview Avenue   
Anaheim, California 92807

Re: k061065 Trade/Device Name: Teco Rapid Fecal Occult Blood (FOB) Card Test Regulation Number: 21 CFR $\$ 864.6550$ Regulation Name: Occult blood test Regulatory Class: II Product Code: KHE Dated: May 26, 2006 Received: June 7, 2006

Dear Mr. Vaeches:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have bee reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 -

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

![](images/da804fa6ed0ab0c3f2f0f293541c94f311327e8ca4d18036bc8910b6cadccd19.jpg)

Robert L. Becker, Jr., MD, PH.D   
Director   
Division of Immunology and Hematology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number (if known):_ K061065

Device Name: Teco Rapid Fecal Occult Blood (FOB) Card Test

Indications or Use: Teco Rapid Fecal Occult Blood (FOB) Card Test is an immunochromatographic assay intended for the determination of human hemoglobin in feces by professional laboratories or physicians offIt isseul odetermi gastrointestal bleedifoundnaumbe gastrointestialdires such as colorectal carcinoma, colon polyps, diverticulitis and ulcerative colitis.

Teo Rapid Fecal Occult Blood (FOB) Card Test is recommended for use in 1) routine physical examination 2 hopial monitring orbleeding n patients, screning or colorectal cancer or gastrointestial bleding

from any source.

Diwision Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k) K061065

Prescription Use âˆš AND/OR Over-The-Counter Use

(Part 21 CFR 801.109)   
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF   
NEEDED)